CHICAGO--(BUSINESS WIRE)-- MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA” or the “Company”), a clinical-stage biopharmaceutical company developing telomere-targeting immunotherapies for ...

Chicago-based Maia Biotechnology said this week that its lead drug candidate, THIO, has gained its generic name, and preclinical data on a different form of the cancer drug suggests it could improve ...

CHICAGO, IL / ACCESSWIRE / November 17, 2023 / More than 300,000 people are diagnosed with brain cancer across the globe each year. Glioblastoma represents the majority of these cases in the U.S., ...

CHICAGO--(BUSINESS WIRE)--MAIA Biotechnology, Inc., (NYSE American: MAIA) (“MAIA”, the “Company”), a targeted therapy, immuno-oncology company focused on developing potential first-in-class oncology ...

On Tuesday, MAIA Biotechnology Inc (NASDAQ:MAIA) announced treatment updates from its Phase 2 THIO-101 trial of THIO sequenced with Regeneron Pharmaceuticals Inc’s (NASDAQ:REGN) cemiplimab (Libtayo) ...

(RTTNews) - MAIA Biotechnology, Inc., (MAIA) Friday said the Food and Drug Administration has granted orphan drug designation to its lead drug candidate THIO for the treatment of glioblastoma, a type ...

Key milestone achieved as Company advances clinical program to full approval trial of ateganosine sequenced with a checkpoint inhibitor in comparison to chemotherapy CHICAGO, Dec. 11, 2025 (GLOBE ...

For patients with advanced non-small cell lung cancer who progressed on two or more prior regimens, THIO with Libtayo elicited positive responses. Among patients with advanced non-small cell lung ...

THIO combined with Libtayo shows a 38% ORR in advanced NSCLC resistant to checkpoint inhibitors, surpassing standard therapies. The phase 2 THIO-101 trial reports a disease control rate of 85% in ...

Never miss a trade again with the fastest news alerts in the world! This headline only article is a sample of real-time intelligence Benzinga Pro traders use to win in the markets everyday. Want the ...